151029-72-0

Basic information

• Product Name: 1H-Benzimidazole,1-(3-chloropropyl)-(9CI)
• Synonyms: 1H-Benzimidazole,1-(3-chloropropyl)-(9CI)
• CAS NO: 151029-72-0
• Molecular Formula: C₁₀H₁₁ClN₂
• Molecular Weight: 194.66074
• Product Categories: BENZIMIDAZOLE
• Mol File: 151029-72-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Benzimidazole,1-(3-chloropropyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole,1-(3-chloropropyl)-(9CI)(151029-72-0)
• EPA Substance Registry System: 1H-Benzimidazole,1-(3-chloropropyl)-(9CI)(151029-72-0)

Safety Data

• Hazardous Substances Data: 151029-72-0(Hazardous Substances Data)

Upstream product

• 53953-47-2 3-(1H-benzimidazol-1-yl)propan-1-ol 
• 51-17-2 benzoimidazole 
• 109-70-6 1.3-chlorobromopropane 

Downstream Products

• 7724-48-3 2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazole 
• 223928-08-3 1-<3-(phenylselanyl)propyl>-1H-benzimidazole 

Relevant articles and documents

Design, synthesis, and evaluation of non-ATP-competitive small-molecule polo-like kinase 1 (Plk1) inhibitors

A series of small-molecule Plk1 inhibitors targeting the substrate-binding pocket were designed through rational drug design for the first time. The designed compounds were synthesized and their activities were evaluated in vitro. Some of the targeted compounds showed potent Plk1 inhibitory activities and anti-proliferative characters. Particularly, 5i showed Plk1 inhibitory activity with an IC50 value of 0.68 μM. Compound 5i also showed cell growth inhibitory activity on HeLa cells with an IC50 value of 0.51 μM, which is about four times more potent compared to thymoquinone. The mechanism of action suggested that 5i was an ATP-independent and substrate-dependent Plk1 inhibitor. Compound 5i demonstrated excellent Plk1 inhibitory selectivity against Plk2, Plk3, and five serine/threonine and tyrosine kinases. Our discovery and structure-activity relationship study may provide useful lead compounds for further optimization of non-ATP-competitive Plk1 inhibitors.

BENZISOXAZOLE PIPERIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE DERIVATIVES AND THEIR USE

The invention relates to a benzisoxazolyl piperidine derivative having the following general formula, a salt or a hydrate thereof, wherein R, X, Y, R′ and T are defined as in the specification. Such compounds have serotonin system modulating effects such as antagonizing effect on 5-HT2A and inhibitory effect on 5-HT reuptake. The compounds have good analgesic and sedative activities with mild toxic and side effects. The invention also relates to a composition comprising said derivative and the use thereof.

Radical cyclisation onto imidazoles and benzimidazoles

New synthetic methodology has been developed for the synthesis of [1,2- a]fused imidazoles and benzimidazoles using intramolecular homolytic aromatic substitution. In the intramolecular substitution, N-(ω-alkyl) radicals are generated using Bu3SnH from N-(ω-phenylselanyl)alkyl side chains. Phenylselanyl groups are used as radical leaving groups to avoid problems in the N-alkylation of imidazoles and benzimidazoles. Arylsulfones for imidazoles, and phenylsulfides for benzimidazoles, are used at the leaving groups in the homolytic substitutions.